|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM354775863 |
| 003 |
DE-627 |
| 005 |
20231226062937.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202211420
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1182.xml
|
| 035 |
|
|
|a (DE-627)NLM354775863
|
| 035 |
|
|
|a (NLM)36972555
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lam, Kieu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Optimizing Lipid Nanoparticles for Delivery in Primates
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.06.2023
|
| 500 |
|
|
|a Date Revised 29.06.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Genevant Sciences Corporation. Advanced Materials published by Wiley-VCH GmbH.
|
| 520 |
|
|
|a Lipid nanoparticles (LNPs) are clinically proven to successfully deliver both small interfering RNA (siRNA) therapeutics and larger mRNA payloads for prophylactic vaccine applications. Non-human primates (NHPs) are generally considered to be the most predictive of human responses. However, for ethical and economic reasons, LNP compositions have historically been optimized in rodents. It has been difficult to translate LNP potency data from rodents to NHPs for intravenously (IV) administered products in particular. This presents a major challenge for preclinical drug development. An attempt to investigate LNP parameters, which have historically been optimized in rodents, is carried out, and seemingly innocuous changes are found to result in large potency differences between species. For example, the ideal particle size for NHPs (50-60 nm) is found to be smaller than for rodents (70-80 nm). Surface chemistry requirements are also different, with almost double the amount of poly(ethylene glycol) (PEG)-conjugated lipid needed for maximal potency in NHPs. By optimizing these two parameters, approximately eight-fold increase in protein expression from intravenously administered messenger RNA (mRNA)-LNP in NHP is gained. The optimized formulations are well tolerated when administered repeatedly with no loss of potency. This advancement enables the design of optimal LNP products for clinical development
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PEG shielding
|
| 650 |
|
4 |
|a lipid nanoparticles
|
| 650 |
|
4 |
|a nanotechnology
|
| 650 |
|
4 |
|a nucleic acid
|
| 650 |
|
4 |
|a particle size
|
| 650 |
|
4 |
|a potency translation
|
| 650 |
|
4 |
|a therapeutics
|
| 650 |
|
7 |
|a Lipid Nanoparticles
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Liposomes
|2 NLM
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 700 |
1 |
|
|a Schreiner, Petra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leung, Ada
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Stainton, Paul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Reid, Steve
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yaworski, Ed
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lutwyche, Pete
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Heyes, James
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 26 vom: 27. Juni, Seite e2211420
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:26
|g day:27
|g month:06
|g pages:e2211420
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202211420
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 26
|b 27
|c 06
|h e2211420
|